» Articles » PMID: 21109987

Involvement of Let-7/miR-98 MicroRNAs in the Regulation of Progesterone Receptor Membrane Component 1 Expression in Ovarian Cancer Cells

Overview
Journal Oncol Rep
Specialty Oncology
Date 2010 Nov 27
PMID 21109987
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

PGRMC1 (progesterone receptor membrane component 1) is part of a multi-protein complex, that is highly expressed in several cancers and is involved in chemoresistance. Although PGRMC1 plays an important role in various cancers, little is known about how PGRMC1 expression is regulated. Therefore, the present study was designed to elucidate the molecular mechanisms that influence PGRMC1 expression in ovarian cancer cells. An in silico approach revealed that the 3'-untranslated region of PGRMC1 contains one highly and one poorly conserved binding site for the microRNA let-7/miR-98 and one highly conserved binding site for miR-141/200a. Luciferase assays and real-time PCRs showed that the let-7 isoforms let-7i and miR-98 target PGRMC1 in SKOV-3 cells. In contrast, the conserved binding site for miR-200a/141 in the 3'-UTR of PGRMC1 is not functional. Stimulation of SKOV-3 cells with progesterone resulted in a decrease in PGRMC1 mRNA levels. Further, an analysis of endogenous let-7i levels in SKOV-3 cells revealed that let-7i expression increased after stimulation with progesterone. Therefore, progesterone may exert its effect on PGRMC1 expression in part by stimulation of let-7i. In conclusion, we propose that PGRMC1 expression is regulated by the miRNAs let-7/miR-98, which could become therapeutic targets, as PGRMC1, like many other targets of let-7, seems to be involved in cancer proliferation and chemotherapy resistance.

Citing Articles

MicroRNA-98: the multifaceted regulator in human cancer progression and therapy.

Hazari V, Samali S, Izadpanahi P, Mollaei H, Sadri F, Rezaei Z Cancer Cell Int. 2024; 24(1):209.

PMID: 38872210 PMC: 11177407. DOI: 10.1186/s12935-024-03386-2.


The microRNA Let-7 and its exosomal form: Epigenetic regulators of gynecological cancers.

Wang F, Zhou C, Zhu Y, Keshavarzi M Cell Biol Toxicol. 2024; 40(1):42.

PMID: 38836981 PMC: 11153289. DOI: 10.1007/s10565-024-09884-3.


Pleiotropy of Progesterone Receptor Membrane Component 1 in Modulation of Cytochrome P450 Activity.

Barata I, Rueff J, Kranendonk M, Esteves F J Xenobiot. 2024; 14(2):575-603.

PMID: 38804287 PMC: 11130977. DOI: 10.3390/jox14020034.


Brain-derived neuerotrophic factor and related mechanisms that mediate and influence progesterone-induced neuroprotection.

Singh M, Krishnamoorthy V, Kim S, Khurana S, LaPorte H Front Endocrinol (Lausanne). 2024; 15:1286066.

PMID: 38469139 PMC: 10925611. DOI: 10.3389/fendo.2024.1286066.


In vitro chemo-preventive efficacy of synthetic progestin Norethindrone in human epithelial ovarian cancer.

Sharma A, Sharma I Med Oncol. 2023; 40(7):195.

PMID: 37270458 DOI: 10.1007/s12032-023-02061-2.